New hope for glioblastoma? early trial tests tinostamustine

NCT ID NCT05432375

Completed Disease control Sponsor: Mundipharma Research Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called tinostamustine in 10 people with a specific type of glioblastoma, a severe brain cancer. The drug was given after standard treatment to see if it is safe and to find the right dose. The goal is to control the disease and delay its return.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tinostamustine
What this could lead to: If it works, this could point toward a new treatment option for a hard-to-treat form of brain cancer.
What could go wrong: This is a very early phase 1 study with only 10 people, focused on safety and dosing. It is too small to prove effectiveness, and the drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Show contact details

Locations

Hospital Universitario Ramón y Cajal, Madrid, Spain

Madrid, Spain
Hospital Universitario Vall d'Hebron, Barcelona, Spain

Barcelona, Spain
Kantonsspital

Sankt Gallen, Switzerland
South Texas Accelerated Research Therapeutics (START)

Madrid, Spain
University Hospital

Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.